Allergy Therapeutics PLC EU Patent Office grants patent for MCT
November 02 2016 - 3:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
02 November 2016
2 November 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
European Patent Office grants new and expanded patent
underpinning Allergy Therapeutics' core Microcrystalline Tyrosine
technology
Patent already granted in the United Kingdom and New Zealand
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, today
announces that the European Patent Office has granted a broad
technology patent relating to the Company's unique Microcrystalline
Tyrosine (MCT) depot adjuvant manufacturing process. This patent
covers the novel manufacture and physiochemical characteristics of
MCT in combination with one or more antigens, further strengthening
the Company's core intellectual property.
The granting of this patent further strengthens Bencard Adjuvant
Systems, the wholly-owned division of Allergy Therapeutics which
specialises in developing and optimising aluminium-free adjuvants
for infectious diseases. Recent data generated have shown how MCT
has a synergistic effect when coupled with another adjuvant from
BAS's portfolio, Virus Like Particles (VLP), to create the adjuvant
system AdSys-VcT. As recently announced, this adjuvant system
demonstrated protective efficacy in a malaria model in a study
performed in collaboration with the University of Oxford, UK.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics,
commented: "We are pleased to expand this key patent and are
excited by the potential for MCT as a core technology within our
adjuvant portfolio to create novel and efficacious vaccines, both
in allergies and also in infectious disease areas such as malaria
and influenza. This further underpins the future pipeline for
products, and the long term success of Allergy Therapeutics to
continue innovating and producing novel medicines."
ENDS
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
About Bencard Adjuvant Systems
Bencard Adjuvant Systems (BAS) is a division of Allergy
Therapeutics UK. Located in UK, BAS specialises in developing and
optimising adjuvants for vaccines against infectious diseases and
allergen immunotherapy. The team at BAS are committed to engaging
in long-term partnerships with those who require BAS's patented
platform of adjuvant technologies to enable successful vaccine or
immunotherapy development. For more information, please contact
www.bencard-as.com.
About Microcrystalline Tyrosine
Microcrystalline Tyrosine (MCT) functions as a depot adjuvant in
the Company's range of subcutaneous immunotherapy products. The use
of a depot upon which to attach an antigen facilitates recognition
by the immune system by providing a slow release system and thus
extending the time available for the immune system to process the
antigen. MCT is comprised of defined crystalline particles of the
amino-acid L-Tyrosine, which is naturally biodegraded by the body
and further used in biological functions. MCT offers a shorter
solubility profile being metabolised in 48 hours(1) and also
exhibits a favourable immune profile in that it preferentially
shifts from an allergic Th1 response to a tolerating Th2
response(2) both of which are preferential to classic depot
adjuvants such as aluminium in short-course allergen
immunotherapy.
References
(1) Baldrick et al, J of toxicology, 2002.
(2) Kundig et al., pending publication.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGGACGUPQPUG
(END) Dow Jones Newswires
November 02, 2016 03:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024